Table 4.
Logistic multivariable analysis for poor adherence to weekly low-dose cisplatin
| aOR | 95% CI | P | |
|---|---|---|---|
| Gender | |||
| Male | Reference | ||
| Female | 0.92 | 0.25–3.16 | 0.9 |
| Smoker | |||
| Never | Reference | ||
| Former | 1.70 | 0.59–5.17 | 0.34 |
| Current | 3.25 | 0.81–14.09 | 0.1 |
| Age | |||
| < 65 | Reference | ||
| 65 or older | 1.27 | 0.53–3.07 | 0.59 |
| KPS | |||
| 90–100 | Reference | ||
| < 90 | 2.67 | 1.10–6.65 | 0.03 |
| Race | |||
| White | Reference | ||
| Other | 3.09 | 0.92–11.56 | 0.08 |
| BMI | |||
| Normal | Reference | ||
| Underweight | 6.89 | 0.43–218 | 0.2 |
| Overweight | 1.7 | 0.58–5.23 | 0.34 |
| Obese | 1.7 | 0.49–6.25 | 0.41 |
| Not available | < 0.001 | NA-1.63e122 | 0.99 |
| Site | |||
| Oropharynx | Reference | ||
| Larynx | 1.63 | 0.48–5.61 | 0.43 |
| Oral cavity | 2.04e7 | < 0.001-NA | 0.99 |
| Other | 1.09 | 0.32–3.61 | 0.88 |
| T staging | |||
| 1–2 | Reference | ||
| 3–4 | 1.22 | 0.48–3.06 | 0.67 |
| N staging | |||
| 0–1 | Reference | ||
| 2–3 | 0.72 | 0.22–2.34 | 0.58 |
| HPV | |||
| Negative | Reference | ||
| Positive | 1.88 | 0.48–8.19 | 0.38 |
| Not available | 1.01 | 0.30–3.56 | 0.98 |
aOR Adjusted odds ratio, 95% CI 95% Confidence interval, BMI Body mass index, KPS Karnofsky performance status, HPV Human papillomavirus